TG Therapeutics to Join Goldman Sachs 45th Annual Global Healthcare Conference

TG Therapeutics, Inc. (NASDAQ: TGTX) has announced that its Chairman and Chief Executive Officer, Michael S. Weiss, will be participating in the Goldman Sachs 45th Annual Global Healthcare Conference. This prominent event will take place at the Loews Miami Beach Hotel in Miami Beach, Florida, from June 10 to June 13, 2024. Specifically, Weiss is scheduled to engage in a fireside chat on Tuesday, June 11, 2024, at 1:20 PM ET.

Interested parties can access a live webcast of this fireside chat via the Events page on TG Therapeutics' website under the Investors & Media section.

TG Therapeutics is a comprehensive, commercial-stage biopharmaceutical company that focuses on acquiring, developing, and commercializing innovative treatments for B-cell diseases. The company boasts an extensive research pipeline and has achieved significant milestones, including U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy). This drug is specifically designed for adult patients with relapsing forms of multiple sclerosis (RMS). This category includes clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. In addition, BRIUMVI has received approval from the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) to treat adult patients with RMS characterized by active disease as determined by clinical or imaging features in both Europe and the United Kingdom.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!